Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | ASPH | Q12797 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30676149 | 0.86 | ALDH1A1 (0.42) | ALDH1A1MAPTKMT2AHDAC1HDAC8 | |
| SCHEMBL30676140 | 0.86 | ALDH1A1 (0.42) | ALDH1A1MAPTKMT2AHDAC1HDAC8 | |
| SCHEMBL2947208 | 0.86 | ALDH1A1 (0.42) | ALDH1A1MAPTKMT2AHDAC1HDAC8 | |
| SCHEMBL10184002 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MAPTKMT2AHDAC1HDAC8 | |
| Trifluoroacetic Acid SCHEMBL30676077 | 0.79 | ASPH (0.41) | ALDH1A1MAPTKMT2AHDAC1HDAC8 | |
| SCHEMBL2952500 | 0.76 | POLB (0.38) | ALDH1A1MAPTKMT2AHPGDHCAR3 | |
| SCHEMBL15078306 | 0.72 | ALDH1A1 (0.45) | ALDH1A1MAPTKMT2AHDAC1HDAC8 | |
| SCHEMBL843129 | 0.72 | PIK3CB (0.57) | ALDH1A1MAPTKMT2ATP53ASPH | |
| SCHEMBL599310 | 0.72 | HCAR3 (0.65) | ALDH1A1MAPTKMT2AHDAC1HDAC8 | |
| SCHEMBL10238695 | 0.72 | GRM5 (0.41) | ALDH1A1MAPTKMT2AHDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102361859-A | Heteroaryl compounds useful as Raf kinase inhibitors | BIOGEN IDEC INC | 2012-02-22 | — | — | CN | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| WO-2010078408-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-6610701-B2 | For therapy and prophylaxis of blood coagulation and cardiovascular disorders | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| US-6610692-B1 | Anticoagulants | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020193398-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-12-19 | — | — | US | disclosed |
| WO-2002064211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-1124822-A4 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1124822-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | ALDH1A1 1934/4885MAPT 4105/4885KMT2A 2394/4885 |
| US-20020193398-A1 | Thrombin inhibitors | F2, F3, TFPI | ALDH1A1 3527/4885MAPT 4249/4885KMT2A 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.